AI Article Synopsis
- The study investigates insulin metabolism in young women with polycystic ovary syndrome (PCOS) who have normal glucose tolerance, comparing them to similar controls.
- Findings reveal that women with PCOS exhibit greater insulin resistance across various body mass index (BMI) categories than matched controls.
- Additionally, these women also display significantly higher fasting and total insulin secretion compared to their controls, suggesting their bodies compensate to maintain normal glucose levels.
Article Abstract
Background: Evidence favours insulin resistance and compensatory hyperinsulinemia as the predominant, perhaps primary, defects in polycystic ovary syndrome (PCOS). The aim of the present study was to evaluate insulin metabolism in young women with PCOS but normal glucose tolerance as compared with age, body mass index and insulin resistance-matched controls to answer the question whether women with PCOS hypersecrete insulin in comparison to appropriately insulin resistance-matched controls.
Research Design And Methods: Sixty-nine cases were divided according to their body mass index (BMI) in normal-weight (N = 29), overweight (N = 24) and obese patients (N = 16). Controls were 479 healthy women (age 16-49 y). Whole body Insulin Sensitivity (WBISI), fasting, and total insulin secretion were estimated following an oral glucose tolerance test (C-peptide deconvolution method).
Results: Across classes of BMI, PCOS patients had greater insulin resistance than matched controls (p<0.0001 for all the comparisons), but they showed higher fasting and total insulin secretion than their age, BMI and insulin resistance-matched peers (p<0.0001 for all the comparisons).
Conclusion: Women with PCOS show higher insulin resistance but also larger insulin secretion to maintain normal glucose homeostasis than age-, BMI- and insulin resistance-matched controls.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976408 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0092995 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Safety of SGLT-2 inhibitors in the management of heart failure in the adult congenital heart disease patient population.
Int J Cardiol Congenit Heart Dis
March 2024
Division of Cardiology, Department of Medicine, Loma Linda University, Loma Linda, CA, USA.
Background: Sodium glucose transporter 2 inhibitors (SGLT-2i) have shown safety and efficacy in patients with heart failure (HF). However, evidence for the use of SGLT-2i in adult congenital heart disease (ACHD) patients with HF is limited.
Methods: We performed a retrospective, single center analysis of 18 patients (>18 years of age) with ACHD and a diagnosis of HF who were initiated on an SGLT-2i.
The Association Between Maternal Body Fat Percentage and the Risk of Gestational Diabetes Mellitus.
Cureus
November 2024
Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Bangkok, THA.
Objective In this study, we aimed to evaluate the relationship between body fat percentage (BFP) and the risk of gestational diabetes mellitus (GDM). Methods We conducted a cohort study involving 336 singleton pregnant women attending an antenatal care clinic before 14 weeks of gestation. Body composition was measured during their first antenatal visit by using a multi-frequency segmental body composition analyzer.
View Article and Find Full Text PDF5-Methyltetrahydrofolate and aqueous extract of () ameliorate diabetes and associated complications in STZ-induced diabetic rats.
3 Biotech
January 2025
Plant Cell Biotechnology (PCBT) Department, Central Food Technological Research Institute (CFTRI), Mysuru, 570 020 India.
Unlabelled: The present study evaluated the effects of 5-methyltetrahydrofolate (5-MTHF) and aqueous extract on diabetes. An in silico docking study with select bioactive compounds showed strong binding affinities of folates with glucose metabolism-related proteins. In vitro assay showed 5-MTHF's superior inhibitory activity on alpha-amylase compared to folic acid.
View Article and Find Full Text PDFMDPAO1 Peptide from Human Milk Enhances Brown Adipose Tissue Thermogenesis and Mitigates Obesity.
Mol Cell Endocrinol
December 2024
Department of Pediatric Laboratory, Affiliated Children's Hospital of Jiangnan University, Wuxi, 214023, China. Electronic address:
The regulatory effect of breastfeeding on offspring metabolism has garnered significant attention as an effective strategy in combating childhood obesity. However, the underlying mechanism remains largely unknown. Through integrated analysis of multiple human milk peptide databases and functional screening, MDPAO1 (milk-derived peptide associated with obesity 1) was identified as having potential activity in promoting the expression of thermogenic genes.
View Article and Find Full Text PDFOptimal use of once-weekly basal insulin efsitora alfa in type 1 and type 2 diabetes: A systematic review and meta-analysis.
Endocr Pract
December 2024
Department of Endocrinology, Indraprastha Apollo Hospitals, New Delhi, Delhi 110076, India.
Objective: No meta-analysis has holistically analyzed and summarized the efficacy and safety of the novel once-weekly basal insulin efsitora alfa in managing type 1 diabetes (T1D) and type 2 diabetes (T2D).
Methods: Clinical trials involving subjects with T1D and T2D receiving once-weekly efsitora alfa in the intervention arm and once-daily basal insulins in the control arm were searched throughout the electronic databases. The primary outcome assessed was the change from baseline in HbA1c.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!